Research
Hormonal
Tanycytic release of VEGF-A is the mechanistic mediator that allows hypoglycemia to increase GLP-1 receptor agonist entry into the brain.
This is a basic science finding. It suggests that the health of specialized brain cells (tanycytes) and their production of VEGF are critical for GLP-1 drugs to work centrally.
StrongSupportsVERY_HIGH confidence
Mechanistically, this phenomenon relies on the release of tanycytic vascular endothelial growth factor A, which is selectively impaired after calorie-rich diet exposure.
Why this rating
Genetic ablation studies (TanycyteDVegfa) provide strong causal evidence.
Source
Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis
Wineke Bakker et al. · Cell Reports · 2022
DOI 10.1016/j.celrep.2022.111698
mechanism_onlyCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →